Similar articles

• Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.

  Gatermann S, Marre R. Gatermann S, et al. Infection. 1991 Mar-Apr;19(2):106-9. doi: 10.1007/BF01645578. Infection. 1991. PMID: 1646771
• [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].

  Blahová J, Hupková M, Krcméry V Sr. Blahová J, et al. Cas Lek Cesk. 1995 Sep 6;134(17):558-61. Cas Lek Cesk. 1995. PMID: 7553760 Slovak.
• Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.

  Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC. Prabhakaran K, et al. Microbios. 1993;76(309):251-61. Microbios. 1993. PMID: 8302203
• Evolution of beta-lactamase inhibitors.

  Rolinson GN. Rolinson GN. Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
• Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

  Sutherland R. Sutherland R. Infection. 1995 Jul-Aug;23(4):191-200. doi: 10.1007/BF01781195. Infection. 1995. PMID: 8522374 Review. No abstract available.